NACASY

The potential occurrence of opioid-induced constipation (OIC) should be considered from the start of opioid therapy in cancer patients, allowing them to receive the right treatment at the right time. This prospective, real-world, multinational study of naloxegol for patients with cancer pain diagnosed with opioid-induced constipation, highlights the importance of using precise and practical tools for an efficient OIC diagnosis and management in a diverse cancer population, thus improving treatment outcomes in this population.¹

View the published study

KYONAL

Opioid-induced constipation (OIC) is a symptom that is hard to treat, and cancer patients should not suffer from it as they are already enduring other effects from opioids and chemotherapies that they receive. This study of naloxegol on symptoms and quality of life related to OIC in patients with cancer has shown sustained efficacy of MOVENTIG (naloxegol) for the treatment of OIC over 12 months in patients with a variety of underlying malignancies.²

View the published study

Dolocheck

Dolocheck is an interactive, easy to access tool to help healthcare professionals evaluate patients’ pain. It brings together a variety of scales used for the assessment of both cancer pain and non-cancer pain and helps enable the follow up of the pain evolution. The scales address acute, chronic, nociceptive and neuropathic pains in one tool.

Access Dolocheck

Talk about constipation

The www.talkaboutconstipation.com website is a new resource aimed at the general public, for people who are taking opioids and who are experiencing constipation and constipation-related symptoms. Its aim is to encourage patients suffering from opioid-induced constipation to speak about their symptoms to their healthcare professional.